FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Macleods Pharma Pioglitazone Hydrochloride Tablets 15 mg Recall

Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manufactured f…

Macleods Pharma Usa Inc · Plainsboro, NJ

Risk level
Class II
Reported by FDA
Oct 23, 2019
Recall ID
D-0140-2020
Check your lot numberHow we source this data

Summary

Macleods Pharma recalled Pioglitazone Hydrochloride Tablets 15 mg starting Sep 23, 2019. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0140-2020 on Oct 23, 2019. Reason: Superpotent. Status: Terminated.

Why it was recalled

Superpotent

Product description

Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India NDC 33342-054-07

Lot numbers, UPCs & expiration codes

Lot # BPF901A, exp. date 12/2021

Where it was sold

Product was shipped to 8 distributors who may have further distributed the product.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0140-2020
Classification
Class II
Status
Terminated
Recall initiated
Sep 23, 2019
FDA report date
Oct 23, 2019
Quantity
31,968 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Macleods Pharma Usa Inc

Original FDA data

Every field from FDA enforcement report D-0140-2020, exactly as published.

Show all FDA fields
City
Plainsboro
State
NJ
Status
Terminated
Country
United States
Event ID
83960
Address
666 Plainsboro Rd Bldg 200 Ste 230
Code information
Lot # BPF901A, exp. date 12/2021
Postal code
08536-0009
Report date
Oct 23, 2019
Product type
Drugs
Recall number
D-0140-2020
Classification
Class II
Recalling firm
Macleods Pharma Usa Inc
Product quantity
31,968 bottles
Termination date
Feb 23, 2021
Reason for recall
Superpotent
Voluntary / mandated
Voluntary: Firm initiated
Product description
Pioglitazone Hydrochloride Tablets USP 15 mg, 30 count bottles, Rx only, Manufactured for: Macleods Pharma USA, Inc., Plainsboro, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India NDC 33342-054-07
Distribution pattern
Product was shipped to 8 distributors who may have further distributed the product.
Recall initiation date
Sep 23, 2019
Initial firm notification
Letter
Center classification date
Oct 11, 2019

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0140-2020, published Oct 23, 2019. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls